Treatment of recurrent suprahyoid cervicofacial lymphangioma with intravenous cyclophosphamide.

Authors:
C Turner
C Turner
Ninewells Hospital
United Kingdom
S Gross
S Gross
UMR 8180 CNRS Université de Versailles St Quentin en Yvelines
France

Am J Pediatr Hematol Oncol 1994 Nov;16(4):325-8

Department of Pediatrics, College of Medicine, University of Florida, Gainesville 32610-0296.

Purpose: Surgical resection of cervicofacial cystic hygromas and lymphangiomas rarely effects complete reduction because of severe anatomic restrictions.

Patients And Methods: With prior knowledge of cyclophosphamide activity against lesions of this type, a formal trial of cyclophosphamide was initiated.

Results: Overall dose escalation therapy resulted in 50% reduction in mass without recurrence after cessation of therapy and with minimal and readily reversible toxicity.

Conclusions: The favorable responses to cyclophosphamide in this study suggest that a prospective randomized trial should be initiated. Certainly, children who have airway and/or esophageal compromise who have failed surgical therapies should be considered for cyclophosphamide treatment.

Download full-text PDF

Source

Still can't find the full text of the article?

We can help you send a request to the authors directly.
November 1994
5 Reads

Publication Analysis

Top Keywords

cyclophosphamide
5
reduction mass
4
50% reduction
4
therapy 50%
4
escalation therapy
4
mass recurrence
4
recurrence cessation
4
minimal reversible
4
therapy minimal
4
cessation therapy
4
dose escalation
4
reversible toxicityconclusions
4
activity lesions
4
cyclophosphamide activity
4
knowledge cyclophosphamide
4
lesions type
4
type formal
4
initiatedresults dose
4
cyclophosphamide initiatedresults
4
formal trial
4

Similar Publications